Search results for "Urea"

showing 10 items of 888 documents

Effect of rhamnolipids on microbial biomass content and biochemical parameters in soil contaminated with coal tar creosote

2019

AbstractThe objective of the present study was to compare the effect of rhamnolipids on the microbial biomass content and the activity of dehydrogenases (DHA), acid phosphatase (ACP), alkaline phosphatase (ALP), and urease (URE) in soil contaminated with two types of coal tar creosote: type C and type GX-Plus. The experiment was carried out on samples of sandy clay loam under laboratory conditions. Coal tar creosote was added to soil samples at a dose of 0 and 10 g·kg−1 DM, along with rhamnolipids at a dose of 0, 10, 100, and 1000 mg·kg−1 DM. The humidity of the samples was brought to 60% maximum water holding capacity, and the samples were incubated at 20°C. Microbial and biochemical param…

Soil testUreaseQH301-705.5polycyclic aromatic hydrocarbonsBiomass010501 environmental sciencescomplex mixtures01 natural sciencesGeneral Biochemistry Genetics and Molecular Biologylaw.inventionBioremediationbioremediationlawmedicineBiology (General)Coal tarsandy clay loampolycycli aromatic hydrocarbons0105 earth and related environmental sciencesGeneral Immunology and MicrobiologybiologyGeneral NeuroscienceAcid phosphatase04 agricultural and veterinary sciencessoil enzymatic activityCreosoteEnvironmental chemistryLoam040103 agronomy & agriculturebiology.protein0401 agriculture forestry and fisheriesGeneral Agricultural and Biological SciencesResearch Articlemedicine.drugOpen Life Sciences
researchProduct

Application of solid-phase microextraction for determining phenylurea herbicides and their homologous anilines from vegetables.

2004

Abstract Residues of metobromuron, monolinuron and linuron herbicides and their aniline homologous were analyzed in carrots, onions and potatoes by solid-phase microextraction (SPME) performed with a polyacrylate fiber. A juice was obtained from food samples that were further diluted, and an aliquot was extracted after sodium chloride (14%) addition and pH control. At pH 4 only the phenylureas were extracted. A new extraction at pH 11 allowed the extraction of phenylureas plus homologous aniline metabolites. Determination was carried out by gas chromatography with nitrogen–phosporus detection (NPD) the identity of the determined compounds was studied by gas chromatography–mass spectrometry.…

Solid-phase microextractionBiochemistryAnalytical Chemistrychemistry.chemical_compoundAnilineVegetablesNanotechnologySample preparationResidue (complex analysis)ChromatographyAniline CompoundsHerbicidesPhenylurea CompoundsOrganic ChemistryExtraction (chemistry)Pesticide Residuesfood and beveragesReproducibility of ResultsGeneral MedicineMonolinuronPesticideReference StandardschemistrySpainSolventsSpectrophotometry UltravioletGas chromatographyChromatography LiquidJournal of chromatography. A
researchProduct

Dynamic covalent urea bonds and their potential for development of self-healing polymer materials

2019

Self-healing polymer materials have drawn rapidly increasing interest over the last decade, and have been studied and used in an ever-increasing range of applications. Herein, we successfully make the covalent urea bond – a pinnacle of stability due to strong resonance effects – dynamic in nature through mediation of zinc salts. The dynamic covalent character of urea in the presence of zinc ions is confirmed through dissociation reaction experiments and quantum chemical calculations of small-molecule model urea compounds. In line with our experiments, the modelling results suggest that the presence of zinc ions speeds up the reaction of urea dissociation by two orders of magnitude via the f…

Solucions polimèriquesMaterials science02 engineering and technologyDissociation (chemistry)chemistry.chemical_compoundLife ScienceGeneral Materials ScienceSelf-healing materialPolyureaVLAGchemistry.chemical_classificationRenewable Energy Sustainability and the EnvironmentOrganic ChemistryGeneral ChemistryPolymerCiència dels materials021001 nanoscience & nanotechnologyIsocyanateOrganische ChemieMonomerchemistryChemical engineeringCovalent bondSiloxane0210 nano-technologyJournal of Materials Chemistry A
researchProduct

Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment.

2010

<i>Objective:</i> To evaluate the safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma (HCC) after progression under sorafenib treatment. <i>Methods:</i> Sunitinib was administered at 37.5 mg daily (4-weeks-on/2-weeks-off schedule) after progression under sorafenib treatment. Adverse events (AEs) were assessed using NCI-CTCAE v3.0, and tumor response was evaluated according to RECIST. Data were analyzed retrospectively. <i>Results:</i> Eleven patients with metastatic disease were treated. Seven patients (64%) presented with no liver cirrhosis, including 3 patients with a history of liver transplantation. The first radiologic…

SorafenibAdultMaleNiacinamideCancer Researchmedicine.medical_specialtyCirrhosisCarcinoma HepatocellularIndolesPyridinesmedicine.medical_treatmentAntineoplastic AgentsLiver transplantationGastroenterologySeverity of Illness IndexDrug Administration ScheduleInternal medicinemedicineSunitinibHumansPyrrolesTreatment FailureAgedRetrospective StudiesSunitinibbusiness.industryPhenylurea CompoundsBenzenesulfonatesLiver NeoplasmsGeneral MedicineMiddle AgedSorafenibmedicine.diseasedigestive system diseasesSurgeryRadiographyTreatment OutcomeOncologyTumor progressionDrug Resistance NeoplasmHepatocellular carcinomaDisease ProgressionFemaleLiver functionLiver cancerbusinessmedicine.drugOncology
researchProduct

Molecular mechanisms of sorafenib action in liver cancer cells.

2012

Sorafenib, a multikinase inhibitor, recently received FDA approval for the treatment of advanced hepatocellular carcinoma (HCC). However, as the clinical application of sorafenib evolves, there is increasing interest in defining the mechanisms underlying its anti-tumor activity. Considering that this specific inhibitor could target unexpected molecules depending on the biologic context, a precise understanding of its mechanism of action could be critical to maximize its treatment efficacy, while minimizing adverse effects. Two human HCC cell lines (HepG2 and Huh7), carrying different biological and genetic characteristics, were used in this study to examine the intracellular events leading …

SorafenibDNA ReplicationNiacinamideCarcinoma HepatocellularDNA RepairTranscription GeneticAngiogenesisCell SurvivalPyridinesApoptosisPharmacologyBiologysorafenib HCC mini-chromosome maintenance genes Dickkopf1 Harakiri Acheron/LARP6 YAP1 cell cycle microarray global gene expression analysisCell Line TumormedicineCell AdhesionHumansneoplasmsMolecular BiologyProtein Kinase InhibitorsCell ProliferationYAP1Neovascularization PathologicCell growthGene Expression ProfilingPhenylurea CompoundsBenzenesulfonatesCell CycleLiver NeoplasmsBiological TransportCell BiologyCell cycleSorafenibmedicine.diseasedigestive system diseasesMechanism of actionHepatocellular carcinomaProtein Biosynthesismedicine.symptomMitogen-Activated Protein KinasesLiver cancerDevelopmental Biologymedicine.drugSignal Transduction
researchProduct

A systems biology perspective on cholangiocellular carcinoma development: focus on MAPK-signaling and the extracellular environment.

2008

Background/Aims Multiple genes have been implicated in cholangiocellular carcinoma (CCC) development. However, the overall neoplastic risk is likely associated with a much lower number of critical physiological pathways. Methods To investigate this hypothesis, we extracted all published genetic associations for the development of CCC from PubMed (genetic association studies, but also studies associating genes and CCC in general, i.e. functional studies in cell lines, genetic studies in humans, knockout mice etc.) and integrated CCC microarray data. Results We demonstrated the MAPK pathway was consistently enriched in CCC. Comparing our data to genetic associations in HCC often successfully …

SorafenibMAPK/ERK pathwayNiacinamideMAP Kinase Signaling SystemPyridinesSystems biologyAntineoplastic AgentsOncogenomicsBiologyCholangiocarcinomaMiceDatabases GeneticmedicineAnimalsHumansGeneOligonucleotide Array Sequence AnalysisHepatologyMicroarray analysis techniquesKinasePhenylurea CompoundsSystems BiologyBenzenesulfonatesComputational BiologySorafenibBiological EvolutionBile Ducts IntrahepaticBile Duct NeoplasmsMultigene FamilyImmunologyKnockout mouseCancer researchExtracellular Spacemedicine.drugJournal of hepatology
researchProduct

Sorafenib in advanced hepatocellular carcinoma

2008

none 25 BACKGROUND: No effective systemic therapy exists for patients with advanced hepatocellular carcinoma. A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma. METHODS: In this multicenter, phase 3, double-blind, placebo-controlled trial, we randomly assigned 602 patients with advanced hepatocellular carcinoma who had not received previous systemic treatment to receive either sorafenib (at a dose of 400 mg twice daily) or placebo. Primary outcomes were overall survival and the time to symptomatic progression. Seconda…

SorafenibMaleNiacinamidemedicine.medical_specialtyCarcinoma HepatocellularPyridinesPlaceboGastroenterologyDouble-Blind MethodInternal medicinemedicineCarcinomaHumansHEPATOCELLULAR CARCINOMAProtein Kinase InhibitorsAgedNeoplasm StagingProportional Hazards Modelsbusiness.industryPhenylurea CompoundsHazard ratioBenzenesulfonatesLiver NeoplasmsGeneral MedicineTREATMENTMiddle AgedSorafenibmedicine.diseaseInterim analysisSurvival AnalysisRecurrent Hepatocellular Carcinomadigestive system diseasesSurgeryHEPATOCELLULAR CARCINOMA; SORAFENIB; TREATMENTChemotherapy AdjuvantHepatocellular carcinomaDisease ProgressionFemaleraf KinasesbusinessLiver cancermedicine.drug
researchProduct

Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma.

2017

Background and aims the Barcelona Clinic Liver Cancer intermediate stage (BCLC-B) of hepatocellular carcinoma (HCC) includes extremely heterogeneous patients in terms of tumor burden and liver function. Transarterial-chemoembolization (TACE) is the first-line treatment for these patients although it may be risky/useless for someone, while others could undergo curative treatments. This study assesses the treatment type performed in a large cohort of BCLC-B patients and its outcome. Methods retrospective analysis of 485 consecutive BCLC-B patients from the ITA.LI.CA database diagnosed with naive HCC after 1999. Patients were stratified by treatment. Results 29 patients (6%) were lost to follo…

SorafenibMaleNiacinamidemedicine.medical_specialtyStandard of careCarcinoma HepatocellularAntineoplastic AgentsGastroenterologyIntermediate stage03 medical and health sciences0302 clinical medicineHCC; BCLC-B; Intermediate stage; Treatment; HepatologyInternal medicinemedicineHumansChemoembolization TherapeuticHCCPropensity ScoreAgedNeoplasm StagingRetrospective Studiesintermediate stageHepatologytreatmentbusiness.industryPatient SelectionPhenylurea CompoundsLiver NeoplasmsSettore MED/09 - MEDICINA INTERNAStandard of CareHepatologyMiddle AgedSorafenibmedicine.diseaseSurvival AnalysisTreatment OutcomeItaly030220 oncology & carcinogenesisHepatocellular carcinomaPropensity score matchingMultivariate Analysis030211 gastroenterology & hepatologyFemaleLiver functionLiver cancerbusinessBCLC-Bmedicine.drug
researchProduct

Sorafenib perpetuates cellular anti-cancer effector functions by modulating the cross talk between macrophages and natural killer cells.

2012

Alternatively polarized macrophages (Mϕ) shape the microenvironment of hepatocellular carcinoma (HCC) and temper anticancer immune responses. We investigated if sorafenib alters the HCC microenvironment by restoring classical macrophage polarization and triggering tumor-directed natural killer (NK) cell responses. In vivo experiments were conducted with sorafenib (25 mg/kg)-treated C57BL/6 wildtype as well as hepatitis B virus (HBV) and lymphotoxin transgenic mice with and without HCC. Monocyte-derived Mϕ or tumor-associated macrophages (TAM) isolated from HCC tissue were treated with sorafenib (0.07-5.0 μg/mL) and cocultured with autologous NK cells. Mϕ and NK cell activation was analyzed …

SorafenibNiacinamideCarcinoma Hepatocellularmedicine.medical_treatmentMacrophage polarizationDrug Evaluation PreclinicalAntineoplastic AgentsApoptosisBiologyMiceliver cancer; therapy; microenvironment; immunology; HCCmedicineAnimalsHumansneoplasmsHepatologyMacrophagesPhenylurea CompoundsLiver NeoplasmsDegranulationNF-kappa BInterleukinMacrophage ActivationSorafenibdigestive system diseasesKiller Cells NaturalMice Inbred C57BLCytokineLymphotoxinImmunologyCancer researchInterleukin 12CytokinesInterleukin 18medicine.drug
researchProduct

Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy

2011

A multicenter randomized controlled trial established sorafenib as a standard of care for patients with advanced hepatocellular carcinoma (HCC). Because the study was prematurely interrupted due to survival benefits in the sorafenib arm, we conducted an observational study to adequately assess risks and benefits of this regimen in field practice. Starting in 2008, all clinically compensated patients with advanced HCC and those with an intermediate HCC who were unfit or failed to respond to ablative therapies were consecutively evaluated in six liver centers in Italy, for tolerability as well as radiologic and survival response to 800-mg/d sorafenib therapy. Treatment was down-dosed or inter…

SorafenibNiacinamideMalemedicine.medical_specialtyCarcinoma HepatocellularDrug-Related Side Effects and Adverse ReactionsPyridinesAntineoplastic AgentsEPATOCARCINOMAlaw.inventionRandomized controlled triallawDrug ToxicityInternal medicinemedicineHumansProspective StudiesHCCProspective cohort studySurvival analysisAgedHCC; sorafenibHepatologybusiness.industryPhenylurea CompoundsBenzenesulfonatesLiver NeoplasmsCarcinomaSettore MED/09 - MEDICINA INTERNAHepatocellularSorafenibMiddle Agedmedicine.diseaseSurvival Analysisdigestive system diseasesSurgeryHepatocellular carcinoma sorafenibRegimenTUMORI DEL FEGATOTolerabilityItalyHepatocellular carcinomaDisease ProgressionsorafenibFemaleLiver cancerbusinessmedicine.drug
researchProduct